Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
GI Oncology Now
Bile Duct Cancer
Colorectal Cancer
Gastroesophageal Cancer
Gastric Cancer
GEP-NETs
GIST
Liver Cancer
Pancreatic Cancer
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Dr. John Fruehauf, Evolent
Dr. John Fruehauf, field medical director at Evolent
Articles by Dr. John Fruehauf, Evolent
Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma
Dr. John Fruehauf, Evolent
Melanoma
|
March 13, 2025
Dr. John Fruehauf details how novel therapies have improved the landscape of metastatic melanoma care.
View More
Dr. John Fruehauf on the Best Therapies for Metastatic Melanoma
Dr. John Fruehauf, Evolent
Melanoma
|
December 19, 2024
Dr. John Fruehauf provided an in-depth overview of treatments for metastatic melanoma.
View More
Dr. John Fruehauf on a New Standard of Care for Stage III Melanoma
Dr. John Fruehauf, Evolent
Melanoma
|
November 7, 2024
Dr. John Fruehauf, Evolent, talks about a new standard of care in the treatment of stage III melanoma.
View More